semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Infection, Bacterial Patient ≥ 18 years old Patient hospitalized in the department of internal medicine within the Hospital Group Paris Saint-Joseph Patient with probabilistic or documented C3G infection Patient affiliated to a social security scheme Francophone patient Patient living at home, in a nursing home or retirement home Patient able to give free, informed and express consent  Patient with allergy to cephalosporins time greater than 24 hours after initiation of antibiotic therapy Patient having been hospitalized in the 3 months preceding the Patient who received antibiotic treatment within 3 weeks prior to Patient being included in another study Pregnant woman Patient under tutorship or curatorship Patient deprived of liberty
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Septic Shock Adult patients (18-80)years 2. Hypotensive (systolic blood pressure<90mm Hg)and require IV vasopressor for more than 24 hours 3. Require IV vasopressor at rate < 8mcg/min and unable to wean for >24 hours  Severe organic heart disease (ejection fraction <30 percent due to higher risk of arrythmia) 2. Bradycardia (HR<50 b/m)due to higher likelihood of symptomatic bradycardia 3. Chronic kidney disease (serum creatinine >2mg/dl) as midodrine and its active metabolites are almost completely execreated in urine 4. Thyrotoxicosis 5. Known allergy to midodrine
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Pulmonary Embolism objectively confirmed pulmonary embolism Informed consent for the participation in the study, according to the requirements of the ethics committee  lack of consent
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Irritable Bowel Syndrome Characterized by Constipation Patients meeting ROME IV for the diagnosis of irritable bowel syndrome that requires that patients have had recurrent abdominal pain on average at least 1 day per week during the previous 3 months that is associated with 2 or more of the following  Related to defecation (may be increased or unchanged by defecation) Associated with a change in stool frequency Associated with a change in stool form or appearance Abdominal Pain Intensity: average of worst daily (in past 24 hours) abdominal pain score of >= 3 on a 0 to 10 point scale over last week Stool Frequency: < or = to 3 Complete Spontaneous Bowel Movement(CSBM) in the previous week Reported bloating rating > or = 2 on 5-point scale [0 (absent) (very severe)] in previous week English speakers, as all surveys are in English  Patients with known hypersensitivity to any component of the trial drugs History of eating disorders Patients with a history of diseases with abdominal symptoms that can resemble IBS Presence of any other known acute or chronic gastrointestinal disorder History of abdominal surgery (cholecystectomy and appendectomy can be tolerated when performed at least one year previously) Pregnancy or breast feeding Current or past history of alcohol dependence Based on lack of adequate scientific evidence to predict drug-drug interaction in vivo, current use of strong inhibitors or inducers for CYP enzymes and participants are instructed not to take any medications that are strong inhibitors or inducers for CYP enzymes during the course of the study Vulnerable Subjects. The study will not vulnerable subjects (such as, those with limited autonomy or those in subordinate hierarchical positions). Children, pregnant women, nursing home residents or other institutionalized persons, students, employees, fetuses, prisoners, and persons with decisional incapacity will not be included
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 1.5-21.0,  Clostridium Difficile Infection Diet Modification Children and adolescents eighteen months old to twenty one years old 2. Diagnosis of C. difficile based upon stool antigen and toxin 3. Minimally active symptomatology based upon 1. 4 or less stools per day 2. No evidence of dehydration 3. No evidence of bandemia or hypoalbuminemia on screening labs 4. Parent/guardian and child must be able to comprehend the consent and assent 5. Parent/guardian and participant must be able to attend study visits at baseline, and weeks +2, +4, +8, +12. 6. Patient must not have had antibiotic treatment directed at C. difficile for at least 1 week  Severe symptoms 1. Abdominal pain that interrupts or inhibits normal activity 2. Fever 3. Vomiting 4. Blood in stool 2. Clinical signs of coexisting acute systemic illnesses (meningitis, sepsis, pneumonia), immunodeficiency, underlying severe chronic diseases, and cystic fibrosis 3. Tobacco, alcohol or illicit drug abuse 4. Currently taking antibiotics at time of enrollment 5. Malnutrition as judged by the ratio of weight to height, 6. Clinical signs of dehydration(CD score>0)
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Clostridium Difficile Infection Infection Communicable Diseases ≥ 18 years old. 2. Medical record documentation of either: a) a current diagnosis or history of recurrent CDI as determined by the treating physician, b) or has had at least two episodes of severe CDI resulting in hospitalization. 3. Is currently taking or was just prescribed antibiotics to control CDI related diarrhea at the time of enrollment. [Note: Subject's CDI diarrhea must be controlled (<3 unformed/loose stools/day) while taking antibiotics during screening.]  Has continued CDI diarrhea despite being on a course of antibiotics prescribed for CDI treatment. 2. Requires systemic antibiotic therapy for a condition other than CDI. 3. Fecal microbiota transplant (FMT) within the past 6 months. 4. FMT with an associated serious adverse event related to the FMT product or procedure. 5. Bezlotoxumab (CDI monoclonal antibodies) if received within the last year. 6. CD4 count <200/mm^3 during Screening. 7. An absolute neutrophil count of <1000 cells/µL during Screening. 8. Pregnant, breastfeeding, or intends to become pregnant during study participation
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Inflammatory Bowel Diseases Ulcerative Colitis Crohn Disease years of age or older Able to provide written informed consent prior to screening and willing to comply with the requirements of the study protocol Have had a diagnosis of ulcerative colitis or Crohn's Disease confirmed by a clinician Have had quiescent disease for the past 3 months or longer as determined by clinician Have had most recent episode of disease within past 24 months as determined by clinician Have had stable IBD medication (other than antibiotics) regimen for the past 3 months or longer Able to speak and read English sufficiently Be able and comfortable using new technology: the app and the smartwatch for 12 months  If female, is pregnant or is breast feeding, or intends to become pregnant within the 12 month study period Unable to provide informed consent or unwilling to participate Use of oral or intravenous antibiotics within 4 weeks prior to screening Current use of glucocorticoid steroid, or nonsteroidal anti-inflammatory drugs (NSAIDs) within the last 3 months Evidence of untreated infection e.g. Clostridium difficile Confirmed diagnosis of extraintestinal manifestations (EIMs) of disease including those that occur concurrent with colitis (episcleritis, scleritis, uveitis, peripheral arthropathies of small and large joints, dermatologic conditions such as erythema nodosum and pyoderma gangrenosum), and those that occur independent of colitis (sacroilitis, ankylosing spondylitis, or primary sclerosing cholangitis) Confirmed diagnosis of other serious disease unrelated to ulcerative colitis or Crohn's Disease Current smoker Unable to speak or read English
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  C.Difficile Diarrhea All patients diagnosed with a hematological disease who had a detection of toxigenic Clostridium difficile in the laboratory within the 2006-2018 period will be included in the study. Hematological patients with a negative CDI test in the same period will be included as controls All patients diagnosed with an hematological/oncological disease or with any immunosuppressive condition, who have a positive detection of toxigenic Clostridium difficile in 2019  N/A
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Severe Clostridium Difficile Infection Severe-Complicated/Fulminant Clostridium Difficile Infection One or more episodes of CDI with symptoms including bowel movements altered in frequency or consistency from baseline Stool test positive for Clostridium difficile by EIA by FDA-cleared assay within 7 days prior to enrollment Age ≥ 18 years Meets any one of the listed for severe or severe-complicated/fulminant disease within 24 hours of intervention Receiving antibiotic treatment for S/SC/F-CDI per current IDSA guidelines. Enrollment details Must either meet ≥1 in severe category or in severe complicated category to be enrolled If the subject meets in both categories, stratify to the higher severity category (severe complicated) Detailed enrollment definitions a. WBC ≥15,000 cells/uL if any value in the time period meets this definition  Evidence of colon/small bowel perforation at the time of study screening Goals of care are directed to comfort rather than curative measures Moderate (ANC < 1000 cells/uL) or severe (ANC < 500 cells/uL) neutropenia Known food allergy that could lead to anaphylaxis Pregnancy a. For subjects of childbearing potential (ages 18 to 55), the subject must have a negative urine pregnancy test within 48 hours of consent and no more than 48 hours prior to first product administration Receipt of FMT or enrollment in a clinical trial for FMT within the last 3 months COVID-19 infection, as defined by a positive nucleic acid or antigen test within the prior 14 days and symptoms consistent with COVID-19 infection
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Recurrent Clostridium Difficile Infection Second or greater episode of CDI (first or greater recurrence) within 12 months, with symptoms including bowel movement altered in frequency or consistency from baseline. 2. Stool positive for C. difficile toxin by EIA or toxin gene by NAAT within 60 days of enrollment. 3. At least one additional prior positive stool test for C. difficile within the prior 12 months (EIA or NAAT as above). 4. Age ≥ 18 years. 5. Minimum of 72 hours of receipt of standard-of-care (vancomycin or fidaxomicin) antibiotic treatment for R-CDI prior to intervention  Evidence of colon/small bowel perforation at the time of study screening 2. Goals of care are directed to comfort rather than curative measures. 3. Moderate (ANC < 1000 cells/uL) or severe (ANC < 500 cells/uL) neutropenia. 4. Known food allergy that could lead to anaphylaxis. 5. Pregnancy a. For subjects of childbearing potential (ages 18 to 55), the subject must have a negative urine pregnancy test within 48 hours of consent and no more than 48 hours prior to first product administration 6. Meeting for severe, severe-complicated/fulminant CDI within 24 hours of planned trial enrollment. We define severe or severe-complicated/fulminant CDI as any one of the following: (1) leukocytosis with peripheral WBC ≥ 15,000 cells/mL; (2) hypotension with systolic blood pressure sustained < 90mmHg for three or more hours or requiring pressors; (3) provider documentation of ileus or radiologic evidence of bowel dilation or megacolon; (4) acute kidney injury with increase in baseline serum creatinine level by ≥50% or new dialysis initiation; (5) serum lactate > 2.2 mmol/L; or (6) ≥ 3 systemic inflammatory response syndrome (SIRS) (which heart rate > 90 beats per minute, respiratory rate > 20 breaths per minute or PaCO2 < 32 mmHg, temperature >38ºC or <36ºC, WBC > 12,000 cells/uL, <4,000 cells/uL, or >10% immature (band) forms). 7. Receipt of FMT or enrollment in a clinical trial for FMT within the last 3 months
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  IBS - Irritable Bowel Syndrome Patients with IBS, ages 18-65 fulfilling Rome IV and asymptomatic controls with no prior history of GI disease or symptoms Participants should be on a stable and consistent diet regimen and should not be following an extreme diet intervention such as gluten-free or a low diet at the time of study participation  Participants with microscopic/lymphocytic/collagenous colitis, inflammatory bowel disease, celiac disease, visceral cancer, chronic infectious disease, immunodeficiency, uncontrolled thyroid disease, history of liver disease or history of elevated AST/ALT > 2.0x the upper limit of normal Prior radiation therapy of the abdomen or abdominal surgeries with the exception of appendectomy or cholecystectomy > 6 months prior to study initiation Ingestion of any prescription, over the counter, or herbal medications which can affect GI transit or study interpretation (e.g. opioids, narcotics, anticholinergics, norepinephrine reuptake inhibitors, nonsteroidal anti-inflammatory drugs, COX-2 inhibitors, bile acid sequestrants) within 6 months of study initiation for asymptomatic volunteers or within 2 days before study initiation for IBS patients. Rescue therapy to facilitate stool collection will be permitted where needed Any females who are pregnant or trying to become pregnant or breast-feeding Antibiotic usage within 3 months prior to study participation Prebiotic or probiotic usage within the 2 weeks prior to study initiation Use of tobacco products within the past 6 months
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Colorectal Cancer Patients with age more than 18 years Presenting to fast track colorectal clinic 1. With bowel symptoms 2. Presenting with anaemia 3. Rectal bleeding  Any patient presenting through routine colorectal clinics 1. With bowel symptoms 2. Presenting with anaemia 3. Rectal bleeding Aged less than 18 years
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Clostridium Difficile Infection-associated Diarrhea and Colitis Signed Informed Consent Male or female no less than 18 years of age Inpatient with a diagnosis of mild-moderate or severe CDAD (first occurrence or first recurrence within 3 months) with: Diarrhea: a change in bowel habits with > 3 liquid or unformed bowel movements (UBM) within 24 hours prior to enrollment, AND Positive C. difficile toxin test on a stool sample produced within 72 hours prior to enrollment  More than one previous episode of CDAD in the 3-month period prior to enrollment Evidence of life-threatening or fulminant CDAD Likelihood of death within 72 hours from any cause History of inflammatory colitides, chronic abdominal pain, or chronic diarrhea Antimicrobial treatment active against CDAD administered for > 24 hours except for metronidazole treatment failures (MTF) Known hypersensitivity or contraindication to teicoplanin Pregnant or nursing females Unable or unwilling to comply with all protocol requirements Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial